Conference abstract · 3 Jul 2013
Conference abstractPublished 1 Mar 2018
Discovery and development of novel DPP IV inhibitor
Shanghai Institute of Materia Medica-CAS, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Type 2 diabetes mellitus (T2DM) is the most common form of the diabetes disease, accounting for about 90-95% of all diagnosed North American cases of diabetes. The main goal of the treatment of type 2 diabetes is to achieve glycemic control as close to the non-diabetic range as practicable, in order to reduce the risk of late-stage complications. The incretin hormone glucagon-like peptide 1 (GLP-1) is a potent simulator of endogenous insulin release. GLP-1 possesses several physiological properties, such as increasing insulin secretion, beta cells mass, and insulin gene expression, inhibiting acid secretion and gastric emptying in the stomach, decreasing food intake by increasing satiety in brain, and promoting insulin sensitivity. Unfortunately, GLP-1 is rapidly degraded in vivo by the serine protease dipeptidyl peptidase-4 (DPP-4); therefore, DPP-4 inhibitors have emerged as a new therapeutic option to treat type 2 diabetes. A novel series of thienopyrimidine derivatives was designed and synthesized, and found to be dipeptidyl peptidase-4 (DPP-4) inhibitors. Among them, compound DC291407 was identified as efficacious, safe, and selective inhibitor of DPP-4 resulting in decreased blood glucose in vivo. Compound DC291407 showed high DPP-4 inhibitory activity (IC50=0.011 Ã?¼M), good selectivity against DPP-4 (selective ratio: DPP-8/ DPP-4>10000; DPP-9/DPP-4>10000), and good efficacy in an oral glucose tolerance test in ICR mice (Fig. 1). DC291407 (0.6 mg/kg, 2 mg/kg, and 6 mg/kg) displayed significant DPP IV inhibition in ob/ob mice at 4 weeks (Fig. 1). The onset dose (2 mg/kg) is much better than alogliptin. Compound DC291407 showed a high clearance (i.e.), high AUC, and a high maximal concentration (Cmax), long half-life, and safety when dosed orally in SD rats and dogs. DC291407 is much better than alogliptin in terms of half-life and AUC in SD rats and dogs. The in vivo antidiabetic studies and desirable pharmacokinetic properties in rat of compound DC291407 showed that it might be a promising new hit for further development of antidiabetic agents. Recent publications 1. Kim D, Wang L, Beconi M, Eiermann G J, Fisher M H et al. (2005) (2R)-4-oxo-4[3-(trifluoromethyl)-5,6-dihydro [1, 2, 4]triazolo[4, 3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151. 2. Weber A E (2004) Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 47:4135-4141. 3. Rasmussen H B, Branner S, Wiberg F C and Wagtmann N (2003) Crystal structure of human dipeptidyl peptidase IV/ CD26 in complex with a substrate analog. Nat Stru Bio 10:19-25.
Subjects
ChemistryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 22 Mar 2022
Design And Discovery Of Novel Lrrk2 Inhibitors
Conference abstract · 5 Sep 2016
Discovery of novel tubulin inhibitors and their synergy with BRAF inhibitors for malignant melanoma
Conference abstract · 2 Nov 2015
Amylin as a Novel Contributor to Alzheimer’s Disease and Natural Product Inhibitor Discovery
Research article · 30 Apr 2015
New tricks for an old dog: discovery, synthesis, in vitro and in vivo antitumor evaluation as well as docking studies of novel rutaecarpine derivatives as Topoisomerase I inhibitors
More from this journal
The newest in Organic Chemistry: Current Research.
Opinion · 9 Jul 2025
Exploring the Intricacies of Chiral Chemistry in Drug Discovery
Commentary · 1 Jul 2025
Cross-Coupling and Chemical Bond Formation of Organotrifluoroborate Nucleophiles in Chemistry
Opinion · 1 Jul 2025
Activation Energy and Reaction Kinetics of Ethyl Acetate Neutral Hydrolysis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalOrganic Chemistry: Current Research
- SubjectChemistry
- BylineArticles whose byline prints “Jiang Wang”
- BylineArticles whose byline prints “Jian Li”
- BylineArticles whose byline prints “Jingya Li”
- BylineArticles whose byline prints “Jia Li”
- BylineArticles whose byline prints “Hong Liu”

